My coffee went up 20c to $5.80. Still worth it.
butters
Junket is so underrated. Def needs a comeback. Pink panna cotta!
I like the way you phrased it as - all the elected members got to vote, but not the unelected ones for obvious reasons.
Reminds me of the story about returning planes and bullet holes https://en.wikipedia.org/wiki/Survivorship_bias
I agree with WhatAmLenny. It might use the same data source but the way information is presented is a lot more usable. Case in point - when it’s going to rain, it gives you a pretty accurate “rain is going to start in x minutes” and a graph of how heavy it will be.
It’s not just about the raw data but how people consume it.
Haha this was good fun.
They reel out of the sky at you like they’re barrelling out of a nightclub bathroom wearing a floral shirt open to the navel, beaks atwitch, roaring a garbled query that sounds disturbingly like: “What did you just say to me?”
Team Bush Stone Curlew!
That was nice of your neighbours. :)
Welp. 3 different cases. G, C and E.
https://www.abc.net.au/news/2025-07-24/qld-12-year-old-abortion-supreme-court-decision/105565078
This is about the third time a story like this has popped up. I wonder if it’s the same girl or separate stories.
Can you go camping in your local park instead of renting? Landlords hate this one trick!
There’s a good explainer article here: https://www.theguardian.com/australia-news/2025/mar/22/us-pharma-trump-australia-pbs-explainer
It all came up in the tariff negotiations - the PBS in Australia means US drug companies don’t make enough money and/or US citizens are paying more for drugs than Australians.
Big pharma in the US claims Australians aren’t paying enough for medicines, considering the billions they pour into research and development, and there are too many delays in getting drug approvals.
PhRMA has asked the Trump administration to put Australia on a “watch list” and wants it to push for change, saying Australia has set the bar too high on cost effectiveness. Australia’s price reductions and “restrictive subsidy caps” meant prices were too low to support investment in innovation, it claims. There are also too many delays in approval processes, it says, adding that the PBS continues to list generic products without the patent owner’s consent.
Developer hasn’t even put in an application yet. Media jumping the gun a bit.